Iron chelators clinical trials
A class of medicines: the studies that test any of its 5 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Iron Chelating Agents.
Get an email when these change. Save the iron chelators studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
- Tagatose
- 2
- Fe(III)-EDTA
- 1
Studies by the year they started
144 studies that test it; most in 2007 (16)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 1 |
| 2002 | 3 |
| 2003 | 8 |
| 2004 | 7 |
| 2005 | 9 |
| 2006 | 6 |
| 2007 | 16 |
| 2008 | 10 |
| 2009 | 7 |
| 2010 | 6 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 9 |
| 2014 | 12 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 2 |
| 2018 | 7 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 78 · Other 66
Novartis Pharmaceuticals (46) · ApoPharma (18) · University Hospital, Lille (5) · Novartis (5) · Ain Shams University (3) · Pennington Biomedical Research Center (2) · National Center for Complementary and Integrative Health (NCCIH) (2) · Robert Lodder (2)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 144
- Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsRecruitingPhase 2Rohan DharmakumarNCT05604131Written as Deferiprone Tablets
- Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaRecruitingPhase 2Amit LotanNCT07759895Written as Deferiprone (DFP)
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingPhase 2Inova Health Care ServicesNCT07023666Written as Deferasirox
- Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell TransplantationRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT06784336Written as Iron chelation
- Effect of Chromium Weight Reduction on Adult Asthma ControlNot yet recruitingNot applicableCairo UniversityNCT07703358Written as Chromium picolinate
- Thinking Zinc: a Study of Zinc Supplements on the Navajo NationRecruitingPhase 2University of New MexicoNCT03908736Written as Zinc Picolinate 15 Mg
- Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedPhase 2/3University Hospital, LilleNCT00943748Written as deferiprone
- Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNot applicableUniversity Hospital, LilleNCT02880033Written as deferiprone
- Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin ResistanceCompletedNot applicableUruk UniversityNCT07371169Written as Chromium picolinate
- Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedPhase 2University Hospital, LilleNCT02164253Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedPhase 2University Hospital, LilleNCT02655315Written as Deferiprone
- Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisCompletedPhase 2/3University Hospital, LilleNCT03293069Written as Deferiprone
- Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA AgentsCompletedPhase 2University Hospital, GrenobleNCT03387475Written as Deferasirox
- Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedPhase 2Novartis PharmaceuticalsNCT03203850Written as Deferasirox FCT
- Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedPhase 2Novartis PharmaceuticalsNCT02435212Written as Deferasirox granule formulation
- Deferiprone to Delay Dementia (The 3D Study)CompletedPhase 2Neuroscience Trials AustraliaNCT03234686Written as Deferiprone 600mg delayed release tablets
- Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadCompletedNot applicableRESnTEC, Institute of ResearchNCT06468423Written as Deferasirox (DFX)
- Study of Parkinson's Early Stage With DeferiproneCompletedPhase 2ApoPharmaNCT02728843Written as Deferiprone
- Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic SyndromeWithdrawnPhase 2Haukeland University HospitalNCT01892644Written as Deferasirox
- Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedPhase 4Chiesi Canada CorpNCT03591575Written as Deferiprone oral solution